Systemic sclerosis & Raynaud's
Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension
Authors' conclusion
The 2022 ESC risk assessment strategy applied at baseline and follow-up predicts survival in SSc-PAH.
Study context
- Population
- Multinational incident cohort of SSc-associated PAH (SSc-PAH)at baseline
- Participants
- 260 participants
- Comparison
- 2022 European Society of Cardiology (ESC) risk strata at baseline and follow-up
- Outcome
- Survival by 2022 ESC risk score
- Follow-up
- Within 2 years
Methodological detailsmultinational, incident cohort, Kaplan-Meier curves, Cox hazards regression, accelerated failure time models
- Multinational
- Incident cohort
- Kaplan-Meier curves, Cox hazards regression, accelerated failure time models
Performance
As reported in the abstract
Survival by 2022 ESC risk strata · follow-up
Baseline: SSc-PAH graded intermediate risk of death
72.2%
Follow-up: classified as low or intermediate-low risk
55.5%
Original publication
Evaluation of the European Society of Cardiology Risk Assessment Score in Incident Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension. Arthritis Care Res (Hoboken). Published 22 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →